Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

1993 • 14,121 citations

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

2003 • 2,874 citations

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

1995 • 2,804 citations

Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials

1996 • 2,541 citations

Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

2003 • 2,522 citations

EORTC QLQ-C30 Scoring Manual

1995 • 2,372 citations

FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets

2003 • 541 citations

Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung.

1993 • 482 citations

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

1995 • 474 citations

Severe acute interstitial pneumonia and gefitinib

2003 • 445 citations

Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.

1997 • 404 citations

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors

2003 • 271 citations

Quality of Life in Patients With Lung Cancer

1998 • 206 citations

Expression of epidermal growth factor receptor (EGF-R) in human lung tumours

1986 • 140 citations

Translation and validation of the standard Chinese version of the EORTC QLQ-C30.

2000 • 133 citations

Prospective Study on Quality of Life Before and After Radical Radiotherapy in Non–Small-Cell Lung Cancer

2001 • 94 citations

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

1999 • 72 citations

The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

2000 • 62 citations

Dose-comparative monotherapy trials of ZD1839 in previously treated non–small cell lung cancer patients

2003 • 61 citations

Treatment of Advanced Non-Small-Cell Lung Cancer: A Review of Current Randomized Clinical Trials and an Examination of Emerging Therapies

2001 • 52 citations

Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer

2001 • 38 citations

Impact of ZD1839 on non–small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy–lung scale

2003 • 29 citations

O-240 Clinical experience with gefitinib (‘Iressa’, ZD1839): an overview of safety and tolerability

2003 • 9 citations